Panelists explore how clinicians differentiate among available androgen receptor pathway inhibitor (ARPI)-based doublet therapies for patients with metastatic castration-sensitive prostate cancer (mCSPC).
Caroline Branch, NP-C
Advertisement
Articles by Caroline Branch, NP-C
Experts unpack evolving mCSPC care, from ARPIs and chemo to PARP and PSMA advances, plus guideline-driven, personalized therapy choices.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Urology Times
1
ARASEC: Clinical Implications and the Role of Multidisciplinary Care
2
2026 AUA/SUO Advanced Prostate Cancer Guideline: Key updates and clinical FAQs
3
Atish Choudhury, MD, PhD, highlights phase 2 data on treatment interruption in mHSPC
4
FDA grants tentative approval to generic enzalutamide tablets
5